Tempus AI Shares Jump After New Angiosarcoma Research Collaboration
Tempus AI shares advanced in morning trading following an announcement of a research collaboration with Angiosarcoma Awareness, Inc. The partnership will leverage roughly 600 de-identified angiosarcoma patient records linked to DNA and RNA sequencing and clinical data, bolstering the companys rare-disease data footprint amid ongoing pharma and dat…